Cargando…
The inhibition of tyrosine kinase receptor signalling in leiomyosarcoma cells using the small molecule kinase inhibitor PTK787/ZK222584 (Vatalanib(®))
Leiomyosarcomas remain challenging tumors to manage and novel therapy strategies besides radiation and conventional chemotherapy are needed. Targeting angiogenesis by inhibition of vascular endothelial growth factor (VEGF) receptor tyrosine kinases (RTKs) of the tumor vasculature with small molecule...
Autores principales: | GAUMANN, ANDREAS K.A., DREXLER, HANNES C.A., LANG, SVEN A., STOELTZING, OLIVER, DIERMEIER-DAUCHER, SIMONE, BUCHDUNGER, ELISABETH, WOOD, JEANETTE, BOLD, GUIDO, BREIER, GEORG |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215578/ https://www.ncbi.nlm.nih.gov/pubmed/25340839 http://dx.doi.org/10.3892/ijo.2014.2683 |
Ejemplares similares
-
Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials
por: Giatromanolaki, A, et al.
Publicado: (2012) -
Effect of VEGF receptor inhibitor PTK787/ZK222548 combined with ionizing radiation on endothelial cells and tumour growth
por: Hess, C, et al.
Publicado: (2001) -
Vatalanib, a tyrosine kinase inhibitor, decreases hepatic fibrosis and sinusoidal capillarization in CCl(4)-induced fibrotic mice
por: Kong, Ling-Jian, et al.
Publicado: (2017) -
Data showing the circumvention of oxaliplatin resistance by vatalanib in colon cancer
por: To, Kenneth K.W., et al.
Publicado: (2016) -
787. Improving ED Sepsis Care
por: Sloan, William A, et al.
Publicado: (2019)